Jacobs Levy Equity Management, Inc Replimune Group, Inc. Call Options Transaction History
Jacobs Levy Equity Management, Inc
- $25.8 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding REPL
# of Institutions
160Shares Held
74.9MCall Options Held
38.4KPut Options Held
43.7K-
Baker Bros. Advisors LP New York, NY11MShares$156 Million1.48% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD11MShares$155 Million0.02% of portfolio
-
Redmile Group, LLC San Francisco, CA4.91MShares$69.2 Million4.65% of portfolio
-
Black Rock Inc. New York, NY4.71MShares$66.5 Million0.0% of portfolio
-
Fcpm Iii Services B.V. Naarden, P73.97MShares$56 Million8.12% of portfolio
About Replimune Group, Inc.
- Ticker REPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,306,700
- Market Cap $695M
- Description
- Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...